Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Sodium Nitroprusside
Generic Name
Sodium Nitroprusside
Active Ingredient
Sodium NitroprussideCategory
Other
Variants
17
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Sodium Nitroprusside, you must consult a qualified healthcare professional.
| .5 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 14335-134 |
| 50 mg/2mL | INJECTION | INTRAVENOUS | 65145-101 |
| .2 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 14335-132 |
| .2 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 14335-133 |
| 50 mg/2mL | INJECTION | INTRAVENOUS | 55150-320 |
| 50 mg/2mL | INJECTION, SOLUTION, CONCENTRATE | INTRAVENOUS | 70436-028 |
| 50 mg/2mL | INJECTION, SOLUTION | INTRAVENOUS | 75907-290 |
| 50 mg/2mL | INJECTION, SOLUTION | INTRAVENOUS | 71288-202 |
| 50 mg/2mL | INJECTION | INTRAVENOUS | 72485-105 |
+ 5 more variants
Detailed information about Sodium Nitroprusside
Sodium Nitroprusside is a potent, rapid-acting vasodilator used for the immediate reduction of blood pressure in hypertensive crises and for the management of acute heart failure. It belongs to the class of nitric oxide-donating vasodilators.
Dosage for Sodium Nitroprusside is highly individualized and must be titrated (adjusted) based on the patient's real-time blood pressure response. According to clinical guidelines (AHA/ACC 2022), the following ranges are typical:
Sodium Nitroprusside is used in pediatric populations for similar indications, though with extreme caution.
In patients with kidney disease, the elimination of thiocyanate (the metabolite) is significantly delayed. Healthcare providers will typically use lower doses, limit the duration of the infusion, and monitor serum thiocyanate levels if the infusion lasts longer than 24-48 hours. If the glomerular filtration rate (GFR) is significantly reduced, the risk of thiocyanate toxicity (psychosis, seizures) increases.
Patients with liver disease may have reduced levels of the enzyme rhodanese, which is necessary to convert toxic cyanide into less toxic thiocyanate. This significantly increases the risk of acute cyanide toxicity. Extreme caution and lower infusion rates are required in this population.
Elderly patients are often more sensitive to the hypotensive effects of the drug. Dosing usually starts at the lower end of the spectrum. Additionally, age-related declines in renal function must be considered when calculating the risk of metabolite accumulation.
Sodium Nitroprusside is never self-administered. It is given by a healthcare professional in a hospital setting.
Because this medication is given as a continuous infusion in a controlled medical environment, a missed dose is unlikely. If an infusion is interrupted, blood pressure will likely rise rapidly (rebound hypertension), and the clinical team will restart the infusion immediately at the appropriate rate.
An overdose of Sodium Nitroprusside can lead to life-threatening hypotension or cyanide toxicity.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. This medication is managed exclusively by critical care specialists.
The most frequent side effects associated with Sodium Nitroprusside are directly related to its intended pharmacological action—lowering blood pressure.
Sodium Nitroprusside is a high-alert medication. Because of its rapid onset and potency, it is only used in clinical environments where the patient can be continuously monitored. The primary safety concern is the prevention of sudden, extreme hypotension and the mitigation of cyanide and thiocyanate toxicities.
As mandated by the FDA, Sodium Nitroprusside carries the following warnings:
Sodium Nitroprusside must NEVER be used in the following conditions:
Sodium Nitroprusside is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown that cyanide can cross the placenta. However, in life-threatening hypertensive emergencies of pregnancy (such as severe preeclampsia or eclampsia), Sodium Nitroprusside may be used if other agents like Hydralazine or Labetalol have failed. The primary risk is potential cyanide toxicity to the fetus. If used, the duration should be kept to an absolute minimum.
It is not known whether Sodium Nitroprusside or its metabolites are excreted in human milk. Because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants from thiocyanate, a decision should be made whether to discontinue nursing or to avoid the drug, taking into account the importance of the drug to the mother. In most cases, the acute nature of the illness requiring Nitroprusside means breastfeeding is temporarily paused.
Sodium Nitroprusside has been used effectively in children, but they require even more vigilant monitoring than adults. Children may be more susceptible to cyanide toxicity due to smaller volumes of distribution and lower levels of the rhodanese enzyme. Dosing starts at 0.3 mcg/kg/min and is titrated carefully. Continuous monitoring of blood pH and oxygen levels is mandatory.
Sodium Nitroprusside is a direct-acting vasodilator. Its chemical structure is Na2[Fe(CN)5NO]·2H2O. When it enters the bloodstream, it reacts with the sulfhydryl groups on the surface of red blood cells and in the vascular wall. This reaction breaks the molecule apart, releasing the nitric oxide (NO) moiety. Nitric oxide then stimulates the enzyme soluble guanylate cyclase in the smooth muscle cells of the vasculature. This enzyme converts GTP into cyclic GMP (cGMP). The cGMP acts as a second messenger, activating protein kinase G, which leads to the dephosphorylation of myosin light chains and the relaxation of the vascular smooth muscle.
The onset of action is nearly instantaneous (within 30 seconds). The peak effect occurs within 1 to 2 minutes. The duration of effect is extremely short; once the infusion is stopped, blood pressure returns to its pre-treatment level within 1 to 10 minutes. This allows for 'minute-to-minute' control of blood pressure.
| Parameter | Value |
|---|---|
Common questions about Sodium Nitroprusside
Sodium Nitroprusside is a potent intravenous medication used primarily for the immediate reduction of blood pressure in patients experiencing a hypertensive crisis. It is also utilized in the management of acute congestive heart failure to reduce the workload on the heart and in surgical settings to induce controlled hypotension, which helps minimize blood loss. Because of its rapid onset and potency, it is only administered in a hospital setting under continuous monitoring. It works by directly relaxing the smooth muscles of the blood vessels, allowing them to widen and lower systemic pressure. It is considered a 'rescue' medication when other oral or slower-acting IV drugs are insufficient.
The most common side effects of Sodium Nitroprusside are related to the rapid drop in blood pressure it causes, including dizziness, nausea, headache, and profuse sweating. Some patients may also experience abdominal pain, muscle twitching, or a rapid heartbeat as the body reacts to the change in vascular tone. These symptoms often resolve if the infusion rate is slowed or stabilized. However, more serious side effects like cyanide or thiocyanate toxicity can occur with prolonged use or high doses. Because patients are in an ICU or emergency setting, medical staff are constantly monitoring for these effects. Alert your nurse immediately if you feel sudden confusion or extreme weakness.
Alcohol consumption is not possible while receiving Sodium Nitroprusside because the drug is only administered to patients in critical condition within a hospital environment. Furthermore, alcohol can interfere with the liver's ability to process various substances and could theoretically complicate the management of blood pressure. Chronic alcohol use may also impair the liver's capacity to detoxify the cyanide released by the medication. Once a patient is discharged and transitioned to oral medications, they should consult their doctor about when it is safe to resume alcohol consumption. Generally, alcohol should be avoided when blood pressure is unstable.
Sodium Nitroprusside is classified as FDA Pregnancy Category C, meaning it should only be used if the potential benefit justifies the potential risk to the fetus. There is evidence that the cyanide released during its metabolism can cross the placenta and potentially harm the developing baby. For this reason, it is generally reserved for life-threatening hypertensive emergencies where other, safer medications like Labetalol or Hydralazine have failed. If it must be used, healthcare providers will use the lowest effective dose for the shortest possible time. Continuous fetal monitoring is usually performed in these high-risk situations. Always discuss the risks and benefits with your obstetrician and critical care team.
Sodium Nitroprusside is one of the fastest-acting medications in the cardiovascular pharmacopeia, with an onset of action that is almost immediate. Most patients will see a significant reduction in blood pressure within 30 to 60 seconds of starting the intravenous infusion. The maximum effect is typically reached within 1 to 2 minutes. This rapid action allows doctors to precisely control blood pressure in emergency situations. Conversely, the drug's effects disappear just as quickly—usually within 1 to 10 minutes after the infusion is turned off. This 'real-time' control is why it is a preferred agent in the ICU.
In a clinical setting, Sodium Nitroprusside is not typically stopped abruptly if the patient has been on a high dose, as this can lead to a dangerous 'rebound' effect where the blood pressure spikes rapidly. Instead, healthcare providers will gradually transition the patient onto oral blood pressure medications. As the oral medications begin to work over several hours, the IV Nitroprusside infusion rate is slowly tapered down. This ensures a smooth and safe transition to long-term blood pressure control. The decision of when and how to stop the infusion is made by the attending physician based on the patient's stability. Patients do not have control over the administration of this IV medication.
Since Sodium Nitroprusside is administered as a continuous intravenous infusion by trained healthcare professionals in a hospital, it is virtually impossible for a patient to 'miss a dose' in the traditional sense. The infusion is controlled by a programmed pump that delivers the medication 24 hours a day. If the IV line becomes dislodged or the pump stops, an alarm will sound, and the medical staff will respond immediately to restart the therapy. Because the drug wears off in just a few minutes, any interruption in service will be noticed quickly through the continuous blood pressure monitoring equipment. Patients do not need to worry about scheduling doses.
Sodium Nitroprusside does not cause weight gain. It is used for very short periods, usually hours to a few days, which is not enough time for metabolic weight gain to occur. Any changes in weight during a hospital stay where this drug is used are more likely related to fluid balance, as patients with heart failure may be losing 'water weight' due to the drug's beneficial effects on the heart and the use of concurrent diuretics. The drug itself does not affect appetite or fat storage. If you notice swelling or rapid weight changes after your hospital stay, you should contact your doctor. These are usually signs of your underlying heart or kidney condition rather than the medication.
Sodium Nitroprusside has several significant drug interactions, most notably with PDE5 inhibitors like Viagra or Cialis, which can cause a life-threatening drop in blood pressure. It also interacts with other blood pressure medications and certain anesthetics used during surgery. However, in a hospital setting, doctors often use Sodium Nitroprusside alongside other medications intentionally to achieve specific goals. The medical team will review your entire medication history to ensure no dangerous combinations occur. It is vital to inform your healthcare providers of all supplements and over-the-counter drugs you were taking before your admission. This allows them to adjust the infusion rate safely.
Yes, Sodium Nitroprusside is available as a generic medication and has been for many years. It was originally marketed under the brand name Nitropress, but several manufacturers now produce generic versions of the 50 mg vials. Because it is an older, off-patent medication, the generic version is the standard of care in most hospitals. The availability of a generic form helps keep the cost of emergency care lower, although the intensive monitoring required during its use remains a significant part of the treatment cost. Regardless of whether a brand or generic version is used, the safety protocols and monitoring requirements remain exactly the same.
Other drugs with the same active ingredient (Sodium Nitroprusside)
> Warning: The medical staff will be monitoring you constantly, but you should alert them immediately if you feel any of the following:
Sodium Nitroprusside is intended for short-term, emergency use only (usually less than 72 hours). It is not used for long-term blood pressure management. Prolonged use significantly increases the risk of thiocyanate accumulation, which can lead to permanent neurological damage if not recognized and treated promptly. Long-term use is also associated with potential thyroid suppression.
The FDA has issued several 'Black Box' warnings for Sodium Nitroprusside, the most serious type of warning:
Report any unusual symptoms to your healthcare provider immediately. They are trained to recognize the early signs of these serious complications.
Patients receiving Sodium Nitroprusside require intensive monitoring:
Patients receiving Sodium Nitroprusside are in a critical care setting and are not permitted to drive or operate machinery. The drug's effects on blood pressure and the potential for dizziness or confusion make these activities impossible.
There is no direct interaction with alcohol, as patients requiring this drug are hospitalized and should not consume alcohol. However, chronic alcohol use can impair liver function, which increases the risk of cyanide toxicity during Sodium Nitroprusside therapy.
Sodium Nitroprusside should not be stopped abruptly if the patient has been on a high-dose infusion for an extended period, as this can cause 'rebound' hypertension. Healthcare providers will typically transition the patient to oral antihypertensive medications and gradually taper the IV infusion rate as the oral drugs take effect.
> Important: Discuss all your medical conditions with your healthcare provider before starting Sodium Nitroprusside. They will assess your risk for toxicity based on your liver and kidney health.
There are no known direct interactions with specific foods because the drug is administered intravenously. However, a patient's overall nutritional status, specifically their levels of Vitamin B12 (cobalamin), can influence how their body handles cyanide. Cobalamin helps in the detoxification of cyanide.
For each major interaction, the mechanism involves either a pharmacodynamic synergy (both drugs doing the same thing to the blood vessels) or a metabolic conflict. The management strategy always involves real-time titration and continuous hemodynamic monitoring by the nursing and medical staff.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, even if you only take them occasionally.
Conditions requiring a careful risk-benefit analysis include:
There are no known major cross-sensitivities with other drug classes, as Sodium Nitroprusside is a unique inorganic salt. However, patients who have had severe adverse reactions to other nitrates (like Nitroglycerin) should be monitored closely for similar idiosyncratic responses.
> Important: Your healthcare provider will evaluate your complete medical history, including any rare genetic conditions, before prescribing Sodium Nitroprusside.
Clinical studies have not identified consistent differences in response between the elderly and younger patients. However, elderly patients are more likely to have decreased renal function. Since thiocyanate is cleared by the kidneys, the risk of thiocyanate toxicity is higher in the elderly. Healthcare providers will typically start at the low end of the dosing range and monitor kidney function closely.
In patients with a GFR below 30 mL/min, thiocyanate accumulation is almost certain if the infusion lasts more than 24 hours. These patients require daily thiocyanate level checks. If levels exceed 10 mg/dL, the infusion should be stopped. Dialysis can be used to remove thiocyanate if toxicity occurs.
In patients with cirrhosis or acute liver failure, the conversion of cyanide to thiocyanate is impaired. These patients can develop cyanide toxicity even at 'normal' infusion rates. Alternative antihypertensives that do not release cyanide are usually preferred in this population.
> Important: Special populations require individualized medical assessment and often require more frequent laboratory testing to ensure safety.
| Protein Binding | Negligible |
| Half-life (Parent Drug) | < 2 minutes |
| Half-life (Thiocyanate) | 3 - 4 days (Normal Renal Function) |
| Metabolism | Non-enzymatic release of NO and Cyanide |
| Excretion | Renal (as Thiocyanate) |
Sodium Nitroprusside is classified as a potent peripheral vasodilator. It is often grouped with other 'Nitrodilators,' though its chemistry and lack of tolerance development distinguish it from organic nitrates like Nitroglycerin or Isosorbide Dinitrate.